Arvinas (ARVN) Cash & Equivalents Growth (3y) (2020 - 2026)

Arvinas (ARVN) Cash & Equivalents Growth (3y) (2020 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 13.29%
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.63%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn -16.07%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -8.88%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 47.78%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Arvinas 529.92 Mn -84.98 Mn - -12.47%

Historic Data

Download Data
DateValue
Mar 31, 2026 -12.47%
Dec 31, 2025 20.68%
Sep 30, 2025 -8.52%
Jun 30, 2025 7.23%
Mar 31, 2025 9.14%
Dec 31, 2024 -2.46%
Sep 30, 2024 -30.67%
Jun 30, 2024 47.01%
Mar 31, 2024 -36.65%
Dec 31, 2023 -19.09%
Sep 30, 2023 8.51%
Jun 30, 2023 61.29%
Mar 31, 2023 53.35%
Dec 31, 2022 106.66%
Sep 30, 2022 121.90%
Jun 30, 2022 101.79%
Mar 31, 2022 29.35%
Dec 31, 2021 223.80%
Sep 30, 2021 245.65%
Dec 31, 2020 167.00%